Breastfeeding and women living with HIV: Is it possible to move beyond the avoidance?

Annunziata Carlea*, Laura Letizia Mazzarelli, Laura Sarno, Caterina Fulgione, Dalila Mantelli and Maurizio Guida

Department of Neurosciences, Reproductive Science and Dentistry, University Federico II of Naples, Via Pansini, 5-80131 Naples, Italy

Received: 25 August, 2022
Accepted: 01 September, 2022
Published: 02 September, 2022

*Corresponding author: Annunziata Carlea, Doctor, Department of Neurosciences, Reproductive Science and Dentistry, University Federico II of Naples, Via Pansini, 5-80131 Naples, Italy, Tel: 00393404812653; E-mail: nunziacarlea@gmail.com

ORCID: https://orcid.org/0000-0003-2607-0528

Keywords: HIV, Breastfeeding, Transmission; Antiretroviral therapy, ART

Copyright License: © 2022 Carlea A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

https://www.peertechzpublications.com

Abstract

The risk of mother-to-infant transmission of HIV 1 during breastfeeding ranges from 10% to 15% in the absence of maternal Antiretroviral Therapy (ART) and infant Antiretroviral (ARV) prophylaxis. WHO guidelines 2016 recommend women living with HIV and fully supported for ART adherence should breastfeed for at least 12 months and up to 24 months or longer. Anyway, in high-income settings, women living with HIV are suggested to avoid breastfeeding, regardless of maternal viral load or antiretroviral therapy status. The advantages of breastfeeding in low and middle-income settings are well recognized. This brief narrative review aims to summarize existing evidence on mechanisms and risk factors for HIV transmission during breastfeeding and the possible prevention strategies in the context of ART adherence.

Introduction

Perinatal HIV transmission may occur during pregnancy, delivery, and breastfeeding [1]. The risk of mother–to–infant transmission of HIV 1 during breastfeeding ranges from 10 to 15% in the absence of maternal Antiretroviral Therapy (ART) and infant Antiretroviral (ARV) prophylaxis. WHO guidelines 2016 recommend women living with HIV and fully supported for ART adherence should breastfeed for at least 12 months and up to 24 months or longer. Anyway, in high-income settings, women living with HIV are suggested to avoid breastfeeding, regardless of maternal viral load or antiretroviral therapy status. The advantages of breastfeeding in low and middle-income settings are well recognized. This brief narrative review aims to summarize existing evidence on mechanisms and risk factors for HIV transmission during breastfeeding and the possible prevention strategies in the context of ART adherence.

Newborn ARV regimens should be started preferably within 6 hours of delivery. 4-week Zidovudine (ZDV) prophylaxis regimen can be used in low-risk newborns whose mothers received ART during pregnancy and had viral suppression within 4 weeks prior to delivery. High-risk newborns should receive a presumptive HIV therapy based on ZDV, lamivudine (3TC) and Nevirapine (NVP) (treatment dose) or ZDV, 3TC, and Raltegravir (RAL) administered from birth up to 6 weeks [2].

However, the overall risk of perinatal transmission decreases to 1% thanks to ART and other prophylactic interventions [3]. Among these, the United States Department of Health and Human Services (DHHS) strongly recommends women living with HIV avoid breastfeeding, regardless of maternal viral load or antiretroviral therapy status (4), due to the safety of formula feeding in high–income settings.

On the other hand, the importance of breastfeeding in low- and middle-income countries is well recognized not only because it provides optimal nutrition but also because it reduces the risk of malnutrition, diarrhea, and respiratory illness [5].

According to WHO guidelines 2016 women living with HIV and fully supported for ART adherence should breastfeed for at least 12 months and for up to 24 months or longer [6].

Breastfeeding can be considered a total nutritional and emotional bond between mother and newborn and represents a powerful source of health benefits for children and mothers [7]. Concerning the newborns, some authors described short-term effects such as the reduction of mortality and morbidity (diarrhea, respiratory infections, and otitis media) [8-10] and long-term effects (an increase of intelligence quotient, reduction of overweight or obesity, type 2 diabetes and of...
also a nearly ten-fold higher risk of HIV transmission when a viral rebound up to six months after delivery [21]. There is among women starting ART during pregnancy. It may lead to studies from both low- and high-income settings, in particular through breastfeeding [19,20].

Mechanisms of transmission

Cell–free (RNA) and cell–associated (DNA) shedding of HIV–1 virus in breast milk are both involved in postnatal transmission. Ndirangu, et al. [16] conducted a case–control study involving thirty–six HIV–positive mothers who transmitted HIV–1 by breastfeeding and thirty–six non–transmitting HIV–1 infected mothers and demonstrated that cell–associated virus level (per ml) is more important than cell–free virus during the early post–partum period (6 weeks). Actually, the antiretroviral therapy suppresses the release of cell–free HIV virus (RNA) and inhibits ongoing cycles of replication, but a cell–associated (CD 4+ T lymphocytes) reservoir of HIV (DNA) remains in the mammary gland and may be activated after extravasation or transepithelial migration. These cells may release viral particles which are considered 17 times more effective in producing HIV antigens than plasma ones [17].

Other cell types, such as macrophages, CD4–positive progenitor T cells, and dendritic cells can be infected in the breast and may play a role in transmission [18].

The effect of long–term ART on these latent cells is still unclear; moreover, a viral threshold in breast milk associated with an increased risk of transmission has not been defined yet.

Risk factors of transmission

A detectable maternal viral load in plasma and advanced maternal disease are strongly associated with HIV transmission through breastfeeding [19,20].

Poor adherence to maternal ART has been described in studies from both low– and high–income settings, in particular among women starting ART during pregnancy. It may lead to a viral rebound up to six months after delivery [21]. There is also a nearly ten–fold higher risk of HIV transmission when

Possible prevention strategies

The most useful tool to promote breastfeeding and prevent HIV mother–to–child transmission is antiretroviral therapy. Pregnant women living with HIV are recommended to use a regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) with a non–nucleoside reverse transcriptase Inhibitor (NNRTI), a boosted protease inhibitor (PI), or an integrase strand transfer inhibitor (INSTI) as the preferred third agent. Dolutegravir is reported to be associated with neural tube defects, so it is not recommended during the first trimester in the US, Europe, and the UK. Even if data concerning the safety of ART during breastfeeding are limited, nowadays it is considered safe for both mother and children, since they are exposed to a lower ARV dose than pediatric established one. A possible consequence of the
ingestion of low concentrations of ARV drugs consists in drug resistance mutations, which may lead to a failure of therapy in adulthood [35,36].

Moreover, WHO also suggests extending the prophylaxis with Zidovudina and Nevirapina in high-risk infants for 12 weeks after delivery (instead of 4-6 weeks after delivery) [37].

However, the PROMISE trial found that infant prophylaxis was equally effective as maternal ART in preventing HIV transmission via breast milk [38].

According to the PROMISE trial results, no clinically relevant differences concerning the growth (length, weight, and head circumference measures) have been observed between the group exposed to mother ART and the group exposed to Nevirapine prophylaxis.

Nevertheless, Stranix-Chibanda, et al. evaluated the effect of the exposure during breastfeeding to tenofovir-containing ART on maternal bone mineral density in comparison with infants treated with nevirapine prophylaxis and they reported a decrease in bone mineral density 74 weeks after the delivery in women belonging the tenofovir-ART arm [39].

Data concerning a safe duration of breastfeeding are not still available. However, according to a recent update of WHO, based on the success of the Option B plus strategy introduced in 2016 [40], HIV+ women should continue to breastfeed for at least 12 months, but ideally for up to 24 months or longer while remaining fully ART adherent [35]. Breastfeeding should be promptly stopped in case of mastitis [34].

The best way to perform postnatal monitoring during breastfeeding is still not well defined [41]. The British HIV Association (BHIVA) recommends testing monthly for both the mother and the infant [34], while the US guidelines recommend a maternal viral load 1-2 times per month and infant monitoring at standard timepoints, following every 3 months and after cessation of breastfeeding [42]. This strict monitoring may lead to improving the patient-doctor/clinician relationship and adherence to therapy. Data regarding the better sample (plasma alone or both plasma and milk) for monitoring HIV viral load are still not available [43].

Limitations of the study

This is a narrative brief review. A comprehensive search was conducted but the majority of the studies deal with low- and middle-income countries. The heterogeneous nature of the interventions and variability in outcomes reported make it difficult to combine studies statistically.

Conclusion

According to our findings, in presence of a suppressed viral load and strong adherence to ART, the risk of HIV transmission through breastfeeding is extremely rare. A more supportive and open approach should be introduced to move beyond the avoidance of breastfeeding both in high-income and low-middle-income settings. Tailored counseling, regarding the risks and benefits of breastfeeding, taking into account the patient’s cultural background, should be recommended. Anyway, in the case of breastfeeding, close viral load monitoring is mandatory.

References

1. Moseholm E, Weis N. Women living with HIV in high-income settings and breastfeeding. J Intern Med. 2020 Jan;287(1):19-31. doi: 10.1111/joim.12986. Epub 2019 Nov 6. PMID: 31614046.

2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Optimizing antiretroviral therapy in the setting of viral suppression. 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/optimizing-antiretroviral-therapy-setting-virologic-suppression.

3. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, Taylor GP, Peckham CS, Tookey PA. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014 Apr 24;28(7):1049-57. doi: 10.1097/QAD.0000000000000212. PMID: 24566097.

4. Committee on Pediatric AIDS. Infant feeding and transmission of human immunodeficiency virus in the United States. Pediatrics. 2013 Feb;131(2):391-6. doi: 10.1542/peds.2012-3543. Epub 2013 Jan 28. PMID: 23359377.

5. Guideline: Updates on HIV and Infant Feeding: The Duration of Breastfeeding, and Support from Health Services to Improve Feeding Practices Among Mothers Living with HIV. Geneva: World Health Organization; 2016. PMID: 27883316.

6. World Health Organization, UNICEF. WHO Guideline. Updates on HIV and infant feeding. Internet. 2016; cited 2018 Nov 28.

7. Alzahar RA. A Review of the Factors Associated With the Timely Initiation of Breastfeeding and Exclusive Breastfeeding in the Middle East. Clin Med Insights Pediatr. 2017 Dec 17;11:1179556517748912. doi: 10.1177/1179556517748912. PMID: 29317851; PMCID: PMC5753894.

8. Sankar M.J, Sinha B, Chowdhury R, Bhandari N, Taneja S, Martines J, Bahl R. Optimal breastfeeding practices and infant and child mortality: a systematic review and meta-analysis. Acta Paediatr. 2015 Dec;104(467):3-13. doi: 10.1111/apa.13147. PMID: 26249674.

9. Horta BL, Victora CG. Short-term effects of breastfeeding: a systematic review of the benefits of breastfeeding on diarrhea and pneumonia mortality. Geneva, Switzerland: World Health Organization; 2013; 13.

10. Bowatte G, Tham R, Allen KJ, Tan DJ, Lau M, Dai X, Lodge CJ. Breastfeeding and childhood acute otitis media: a systematic review and meta-analysis. Acta Paediatr. 2015 Dec;104(467):85-95. doi: 10.1111/apa.13151. PMID: 26265016.

11. Victora CG, Horta BL, Loret de Mola C, Quevedo L, Pinheiro RT, Gigante DP, Barros FC. Association between breastfeeding and intelligence, educational attainment, and income at 30 years of age: a prospective birth cohort study from Brazil. Lancet Glob Health. 2015 Apr;3(4):e199-205. doi: 10.1016/S2214-109X(15)00022-2. PMID: 25794674; PMCID: PMC4365917.

12. Horta BL, Loret de Mola C, Victora CG. Long-term consequences of breastfeeding on cholesterol, obesity, systolic blood pressure and type 2 diabetes: a systematic review and meta-analysis. Acta Paediatr. 2015 Dec;104(467):30-7. doi: 10.1111/apa.13133. PMID: 26192560.

13. Amityl EL, Keinan-Boker L. Breastfeeding and Childhood Leukemia Incidence: A Meta-analysis and Systematic Review. JAMA Pediatr. 2015 Jun;169(6):e151025. doi: 10.1001/jamapediatrics.2015.1025. Epub 2015 Jun 1. Erratum in: JAMA Pediatr. 2015 Aug;169(8):791. Erratum in: JAMA Pediatr. 2015 Aug;169(8):791. Erratum in: JAMA Pediatr. 2015 Nov;169(11):1872. PMID: 26030516.
Carlea A, Mazzarelli LL, Sarno L, Fulgione C, Mantelli D, et al. (2022) Breastfeeding and women living with HIV: Is it possible to move beyond the avoidance? J HIV Clin Sci Res 9(1): 005-009. DOI: https://dx.doi.org/10.17352/2455-3786.000133
39. Stranix-Chibanda L, Tierney C, Sebikari D, Alizire J, Dadabhai S, Zanga A, Mukwasi-Kahari C, Vhembo T, Violari A, Theron G, Moodley D, George K, Fan B, Sommer MJ, Browning R, Mofenson LM, Shepherd J, Nelson B, Fowler MG, Siberry GK. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. PLoS One. 2021 Feb 5;16(2):e0246272. doi: 10.1371/journal.pone.0246272. PMID: 33544759; PMCID: PMC7864465.

40. Zijenah LS, Bandason T, Bara W, Chipiti MM, Katzenstein DA. Mother-to-child transmission of HIV-1 and infant mortality in the first six months of life, in the era of Option B Plus combination antiretroviral therapy. Int J Infect Dis. 2021 Aug;109:92-98. doi: 10.1016/j.ijid.2021.06.036. Epub 2021 Jun 21. PMID: 34161799.

41. Lesosky M, Raboud JM, Glass T, Brunmel SS, Ciaranello AL, Currier JS, Essajee S, Havir DV, Koss CA, Ogwu A, Shapiro RL, Abrams EJ, Myer L. Comparison of guidelines for HIV viral load monitoring among pregnant and breastfeeding women in sub-Saharan Africa. AIDS. 2020 Feb 1;34(2):311-315. doi: 10.1097/QAD.0000000000002400. PMID: 31634186; PMCID: PMC7060505.

42. Waitt C, Low N, Van de Perre P, Lyons F, Loutfy M, Aebi-Popp K. Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings. Lancet HIV. 2018 Sep;5(9):e531-e536. doi: 10.1016/S2352-3018(18)30098-5. Epub 2018 Jun 27. PMID: 29960731.

43. Greene S, Ion A, Kwamba G, Lazarus L, Loutfy M. HIV Mothering Study Team. Surviving Surveillance: How Pregnant Women and Mothers Living With HIV Respond to Medical and Social Surveillance. Qual Health Res. 2017 Dec;27(14):2088-2099. doi: 10.1177/1049732317725219. Epub 2017 Aug 17. PMID: 28814159.